in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch
Neurol 55: 1089–1095
Brannan T, Martinez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase inhibition
increases striatal L-dopa and dopamine an in vivo study in rats. Neurology 42: 683–
685
Djaldetti R, Melamed E (1998) Management of response fluctuations: practical guidelines. Neurology 51: S36–40
Grace AA, Onn SP (1989) Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 9: 3463–
3481
Guldberg HC, Marsden CA (1975) Catechol-O-methyltransferase: pharmacological as- pects and physiological role. Pharmacol Rev 27: 135–206
Johnson SW, North RA (1992) Two types of neurons in the rat ventral tegmental area and
their synaptic inputs. J Physiol 450: 455– 468
Kaakkola S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and
L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine
in rat striatum. J Neurochem 60: 137–144
Kurth MC, Adler CH (1998) COMT inhibition: a new treatment strategy for Parkinson's
disease. Neurology 50: S5 3–14
Lacey MG, Mercuri NB, North RA (1987) Dopamine acts on D2 receptors to increase
potassium conductances in neurones of the rat substantia nigra zona compacta.
J Physiol 392: 397–416
Lacey MG, Mercuri NB, North RA (1989) Two cell types in rat substantia nigra zona
compacta distinguished by membrane properties and the action of dopamine and
opioids. J Neurosci 9: 1233–1241
Lacey MG, Mercuri NB, North RA (1990) Actions of cocaine on rat dopaminergic
neurones in vitro. Br J Pharmacol 98: 731–735
Maj J, Rooz Z, Skuza G, Sowiska IT, Superata J (1990) Behavioural and neurochemical
effects of RO 40-7592, a new COMT inhibitor with a potential therapeutic activity in
Parkinson's disease. J Neural Transm [PD-Sect] 2: 101–112
Mannisto PT (1994) Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1: 172–179
Mercuri NB, Calabresi P, Bernardi G (1990) Responses of rat substantia nigra compacta
neurones to L-DOPA. Br J Pharmacol 100: 257–260
Mercuri NB, Bonci A, Calabresi P, Stratta F, Bernardi G (1995) Properties of the
hyperpolarization-activated cation current I in rat midbrain dopaminergic neurons.
h

Eur J Neurosci 7: 462– 469
Mercuri NB, Bonci A, Bernardi G (1997a) Electrophysiological pharmacology of the
autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs.
Trends Pharmacol Sci 18: 232–235
Mercuri NB, Scarponi M, Bonci A, Siniscalchi A, Bernardi G (1997b) Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses
in rat midbrain dopaminergic cells. J Neurosci 17: 2267–2272
Mercuri NB, Scarponi M, Federici M, Bonci A, Siniscalchi A, Bernardi G (1998) Modification of levodopa responses by deprenyl (selegiline): an electrophysiologycal and
behavioural study in the rat relevant to Parkinson's disease. Ann Neurol 43: 613–617
Napolitano A, Zurker G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O- methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Eur J Pharmacol 273: 215–221
Schoepp DD, Azzaro AJ (1982) The role of type A and type B monoamine oxidase in the
metabolism of released [3H]dopamine from rat striatal slices. Biochem Pharmacol
31: 2961–2968
Weiner N, Molinoff PB (1989) Storage and release of catecholamines. In: Siegel G,
Agranoff B, Albers RW, Molinoff P (eds) Basic neurochemistry: molecular, cellular,
and medical aspects. Raven Press, New York, pp 236–239
